Press "Enter" to skip to content

Patent delisted for Abbvie drug KALETRA

1
Copyright © DrugPatentWatch. Originally published at Patent delisted for Abbvie drug KALETRA

Annual Drug Patent Expirations for KALETRA
Kaletra is a drug marketed by Abbvie and is included in three NDAs. It is available from three suppliers.

KALETRA drug price trends.

Drug patent litigation for KALETRA.

The generic ingredient in KALETRA is lopinavir; ritonavir. Three suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at Patent delisted for Abbvie drug KALETRA
Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

Do NOT follow this link or you will be banned from the site!